AI
| Followers | 843 |
| Posts | 122988 |
| Boards Moderated | 9 |
| Alias Born | 09/05/2002 |
Wednesday, November 17, 2010 10:47:09 PM
NVS’ DEB025, a cyclophilin inhibitor for HCV, can potentially work
as monotherapy or in combination with other HCV drugs. DEB025
does not lead to rapid resistance when given as monotherapy because
it blocks a host protein rather than a viral protein. Below are 50-day
data for DEB025 dosed for 28 days as monotherapy or in combination
with Pegasys without ribavirin. Genotype-1/4 data are on the left and
genotype-2/3 data are on the right. (‘LQ’ = level of quantitation.)
Source: http://www.novartis.com/downloads/investors/presentations-events/pipeline-update/2010/2010-11-17-making-science_happen.pdf (slide #21)
as monotherapy or in combination with other HCV drugs. DEB025
does not lead to rapid resistance when given as monotherapy because
it blocks a host protein rather than a viral protein. Below are 50-day
data for DEB025 dosed for 28 days as monotherapy or in combination
with Pegasys without ribavirin. Genotype-1/4 data are on the left and
genotype-2/3 data are on the right. (‘LQ’ = level of quantitation.)
Source: http://www.novartis.com/downloads/investors/presentations-events/pipeline-update/2010/2010-11-17-making-science_happen.pdf (slide #21)
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
